TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06638931
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The intervention consists of administering Nivolumab 480 mg intravenously every 4 weeks, with a +5 day window for postponement but not for advancement of treatment. Treatment will continue until limiting toxicity, disease progression, or for a maximum period of 12 months (13 cycles) as maintenance therapy, provided the patient maintains stable disease, a partial response, or a complete response. Patients who are off treatment for more than 56 days (2 cycles) due to Nivolumab-related toxicities or other clinical issues will be discontinued from the protocol.~After 12 months of treatment or in the event of study discontinuation for any reason, patients will be followed by the research team via telephone every 60 days, with a +/- 7 day window, until death.
Study: NCT05479981
Drug: AOC 1001
Normalized name: AOC 1001
DrugBank: AOC 1001 (DB18620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOC 1001 will be administered by intravenous (IV) infusion.
Study: NCT06640946
Drug: Topical lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical lidocaine cream prior to laser follicle ablation
Study: NCT06640946
Drug: Sham cream
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream without lidocaine will be placed and removed before laser.
Study: NCT05406401
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV or oral administration (per local guidelines)
Study: NCT05176665
Drug: EMB-01
Normalized name: EMB-01
DrugBank: EMB-01 (DB16091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses).
Study: NCT05689099
Drug: Semaglutide B, 1.34 mg/mL
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 1.34 mg/mL subcutaneously.
Study: NCT05689099
Drug: Semaglutide B, 0.68 mg/mL
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive single dose of 0.5 mg Semaglutide B, 0.68 mg/mL subcutaneously.
Study: NCT06360055
Drug: Dabigatran Etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive a single oral dose of 110mg (low dose specification in the instructions) or lower of dabigatran etexilate on an empty stomach on the morning of day 1 and day 16 of the trial period.
Study: NCT06082843
Drug: Avenciguat (BI 685509)
Normalized name: Avenciguat
DrugBank: Avenciguat (DB18882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avenciguat (BI 685509)
Study: NCT05989997
Drug: 68Ga-NOTA-SNA002
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-NOTA-SNA002 should be injected intravenously slowly for no less than 1min.
Study: NCT06564935
Drug: Heptaminol Hydrochloride
Normalized name: heptaminol hydrochloride
DrugBank: Heptaminol (DB13574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: heptaminol hydrochloride will be administrated in its solution form 4ml/kg. The mean dose used will be 25 drops = 150 mg and will be given 1.5 to 2 hours before spinal anesthesia
Study: NCT01296204
Drug: BB4 antibody-Iodine 131
Normalized name: Iodine-131 anti-b1 antibody
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of an antibody after labelling with Iodine 131
Study: NCT04392622
Drug: D-Limonene Gelcaps
Normalized name: D-(+)-limonene
DrugBank: (4R)-limonene (DB08921)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally at 2 to 8 grams daily
Study: NCT04392622
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care -Cisplatin as 100 mg/m2 IV
Study: NCT06560892
Drug: Bupivacaine injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients received intraperitoneal bupivacaine 50 ml 0.25% + 5 ml normal saline.
Study: NCT06560892
Drug: Dexmedetomidine injection
Normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were given intraperitoneal bupivacaine 50 ml 0.25% + dexmedetomidine 1 μg/kg with normal saline 5 ml.
Study: NCT06563778
Drug: Chidamide; Decitabine; Anti-PD-1 Antibody
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chidamide 10mg/day, day1-4; 20mg/day, day 8,11, 15, 18. Decitabine 10mg/day, day1-5. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
Study: NCT06563778
Drug: Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody
Normalized name: Brentuximab Vedotin
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab Vedotin 1.2-1.8mg/kg day 1, Bendamustine 70-90mg/m2 day1-2, Anti-PD-1 antibody day 2. Physicians will decide which immune checkpoint inhibitors will be used during treatment.
Study: NCT05360784
Drug: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brimonidine tartrate ophthalmic solution 0.025% preservative-free formulation. Participants will instill 1 drop of the assigned investigational drug in each eye 4 times a day approximately 4 hours apart for up to 4 consecutive weeks.
Study: NCT06083454
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given intravenous (IV) infusion as monotherapy or in combination with pharmacological ascorbate
Study: NCT06083454
Drug: Pharmacological ascorbate
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given intravenously in combination with Durvalumab
Study: NCT05548296
Drug: ACR-368
Normalized name: ACR-16
DrugBank: ACR-16 (DB05371)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACR-368 is an experimental drug
Study: NCT05548296
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is a standard of care given at ultralow dose in combination with the experimental drug ACR-368
Study: NCT06414031
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous administration
Study: NCT05014919
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablets
Study: NCT04981912
Drug: HDMP + rituximab as a means of debulking prior to initiating venetoclax.
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Patients will receive HDMP + Rituximab for 1 cycle, followed by reassessment of Tumor Burden,~* If Tumor Burden classification is low after HDMP + Rituximab (lymph nodes \< 5cm in diameter AND absolute lymphocyte count \< 25k/uL), patients will initiate venetoclax dose ramp-up, with ramp-up schedule according to venetoclax package insert.~* Patients who still have a disease burden (lymphadenopathy \> 5 cm or ALC \> 25k/iL) that meets criteria for medium or high risk of TLS after 1 cycle of HDMP + Rituximab are given the option to repeat a 2nd cycle of HDMP + Rituximab prior to venetoclax dose ramp-up.
Study: NCT04708847
Drug: GYM329
Normalized name: GYM329
DrugBank: GYM329 (DB18590)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GYM329 subcutaneous injection
Study: NCT04849273
Drug: TPX-0131
Normalized name: TPX-4589
DrugBank: TPX-4589 (DB18604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TPX-0131 tablets
Study: NCT06549231
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: one course of IV rituximab consisting of an infusion of 1000 mg rituximab (diluted in 500 mL of saline 0.9 % sodium chloride) will be given at day 1, day 15 and an infusion of 500 mg rituximab (in 500 mL of saline 0.9 % sodium chloride) at week 24;
Study: NCT04724837
Drug: Zibotentan
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive zibotentan as per the arms they are randomized.
Study: NCT04724837
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 10 mg dapagliflozin as per the arms they are randomized.
Study: NCT03763370
Drug: Belantamab mafodotin 2.5 mg/kg IV Q3Weeks + Vd (BVd)
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Belantamab mafodotin~•Belantamab mafodotin 2.5 milligram per kilogram (mg/kg) intravenous (IV) will be administered at every cycle, once every 3 Weeks, on Day 1 of every cycle, until completion of treatment.~Drug: Bortezomib •Bortezomib will be administered based on the full prescribing information, for the first 8 Cycles~Drug: Dexamethasone~•Dexamethasone will be administered based on the full prescribing information, for the first 8 Cycles
Study: NCT03763370
Drug: Belantamab mafodotin 2.5/1.9 mg/kg IV Q4Weeks + Pd (BPd)
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Belantamab mafodotin:~* Cycle 1: Belantamab mafodotin 2.5 mg/kg IV administered once~* Cycle 2 onward: Belantamab mafodotin 1.9 mg/kg IV administered once every 4 weeks until completion of treatment~Drug: Pomalidomide •Pomalidomide will be administered at every cycle, based on the full prescribing information~Drug: Dexamethasone~•Dexamethasone will be administered at every cycle, based on the full prescribing information
Study: NCT05393427
Drug: BL-B01D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT06120842
Drug: Bimatoprost Implant System (High Dose)
Normalized name: bimatoprost Drug Implant
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost Implant System (High Dose) used in combination with the SpyGlass IOL
Study: NCT06120842
Drug: Bimatoprost Implant System (Low Dose)
Normalized name: bimatoprost Drug Implant
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bimatoprost Implant System (Low Dose) used in combination with the SpyGlass IOL
Study: NCT06120842
Drug: Timolol Maleate Ophthalmic Solution, 0.5%
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol Maleate Ophthalmic Solution 0.5% BID
Study: NCT05852340
Drug: Ritlecitinib
Normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ritlecitinib 1 x 30 mg intact BiC (Treatment Arms A, E)~ritlecitinib 1 x 30 mg intact BiC sprinkled on soft foods (Treatment Arms B, C, D)
Study: NCT06484881
Drug: Topical minoxidil 5%
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical minoxidil 5%
Study: NCT04344873
Drug: Abatacept 10 mg/kg
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept injection at day twenty eight and day forty two.
Study: NCT05916937
Drug: omalizumab 300 mg every four weeks
Normalized name: omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Continue standard treatment with omalizumab 300 mg every four weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12.
Study: NCT05916937
Drug: omalizumab 300 mg every six weeks
Normalized name: omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment in an extended interval of omalizumab 300 mg every six weeks from week 12 to week 36.~Both arms are treated with omalizumab 300 mg from week 0 to week 12.
Study: NCT05810597
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05645380
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC=6, IV
Study: NCT05645380
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, IV
Study: NCT05645380
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg, IV
Study: NCT05286619
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg will be administered on Day 1 every 3 weeks for up to 24months
Study: NCT05286619
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin at 35 mg/m2 IV using a split dose regimen on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles.
Study: NCT05286619
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin at AUC 5 IV on Day 1 of each 3-week cycle, up to 6 cycles.
Study: NCT05286619
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1250mg/m2 IV on Day 1 and Day 8 of each 3-week cycle, up to 6 cycles
Study: NCT03608631
Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
Normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06570850
Drug: Colistin Sodium Methanesulfonate
Normalized name: Colistin methanesulfonic acid
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colistin (colistinmethate soidum) 5 mg/kg/day intravenous (dosage will be adjusted according to creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
Study: NCT06570850
Drug: Colistin Sodium Methanesulfonate plus Fosfomycin
Normalized name: Colistin methanesulfonic acid
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous colistin(dosage is same as colistin group) plus intravenous fosfomycin(dosage will be adjusted according to MIC and creatinine clearance). The duration of treatment ranges from 10 to 14 days, depending on the site of infection and clinical responsiveness.
Study: NCT06108947
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin discontinuation
Study: NCT05724069
Drug: Velusetrag
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
Study: NCT04905173
Drug: Amyl nitrite inhalation
Normalized name: Amyl Nitrite Inhalation Solution
DrugBank: Amyl Nitrite (DB01612)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will inhale amyl nitrite prior to undergoing echocardiographic imaging. This is administered according to current laboratory protocol and is part of standard of care. This is an FDA-regulated drug that will be used as a control and will not be studied experimentally.
Study: NCT06640439
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 0.3 g bid for 3 days, metronidazole 0.1 g tid, and cefaclor 0.375 g bid for 7 days after surgery
Study: NCT04905212
Drug: Telitacicept 160mg
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.
Study: NCT04905212
Drug: Telitacicept 240mg
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.
Study: NCT05846906
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral sildenafil (Respatio® 20mg )
Study: NCT05846906
Drug: Clomiphene Citrate 50mg
Normalized name: CLOMIPHENE CITRATE 50MG TAB
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: used for ovionulation induct
Study: NCT05294172
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-6 cycles for combined therapy
Study: NCT05294172
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-6 cycles for combined therapy.
Study: NCT01280669
Drug: Intravitreal injection 440mcg
Normalized name: Dexamethasone Intravitreal Implant
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
Study: NCT01280669
Drug: Intravitreal injection of sirolimus 880mcg
Normalized name: sirolimus Injection
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
Study: NCT06101420
Drug: Vonoprazan
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Venoprazan 20mg twice daily,clarithromycin 500mg twice daily,amoxycillin 1 gm twice daily,esomeprazole 20mg twice daily,levofloxacin 500mg a single tablet daily,doxycicline 100mg a single capsule daily and nitazoxanide 500mg twice daily
Study: NCT04947189
Drug: Seviteronel-D (Seivteronel in combination with dexamethasone)
Normalized name: Seviteronel
DrugBank: Seviteronel (DB12275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of Seviteronel-D (Serivteronel and dexamethasone) in the treatment of androgen receptor positive solid tumours.
Study: NCT04947189
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of docetaxel chemotherapy for solid tumours
Study: NCT05879029
Drug: Jinsang Liyan Capsule; Rabeprazole enteric-coated tablets.
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the experimental group were given Jinsang Liyan Capsule + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
Study: NCT05879029
Drug: Jinsang Liyan Capsule placebo; Rabeprazole enteric-coated tablets.
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in the control group were given Jinsang Liyan Capsule placebo + Rabeprazole enteric-coated tablets according to the requirements, and were followed up at 4 and 8 weeks. VAS and RSI scores were used to judge the improvement degree of patients' symptoms.
Study: NCT06068621
Drug: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1. Azacytidine (75 mg/m2/day, days 1 to 7).~2. Cytarabine (75-100 mg/m2 bid, days 1 to 5).~3. Aclacinomycin(20 mg/day, days 1,3,5).~4. Chidamide (30 mg/day , days 1,4,8,11).~5. Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~6. Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)
Study: NCT06068621
Drug: 3+7
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA regimen:~1. Idarubicin (8-10 mg/m2) for 3 days .~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~1. Daunorubicin(60 mg/m2) for 3 days.~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.
Study: NCT05291910
Drug: Inetetamab
Normalized name: Inetetamab
DrugBank: Inetetamab (DB17457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 to 90 minutes IV infusion every three weeks
Study: NCT05291910
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg intravenously every 3 weeks
Study: NCT05291910
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 130mg/m2, IV , D1, D8, q3w
Study: NCT06456060
Drug: Honey
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Honey soaked in a sterile gauze will be applied to cover the socket.
Study: NCT05545059
Drug: Sacubitril/valsartan
Normalized name: SACUBITRIL/VALSARTAN
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In sacubitril/valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg, sacubitril/valsartan 200mg to treat. The initial dose of sacubitril/valsartan will be 100mg per day and will be doubled to 200mg per day after 2 weeks then maintain until the end of the 8-week treatment period.
Study: NCT05545059
Drug: valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In valsartan group, patients will receive amlodipine 10mg, hydrochlorothiazide 25 mg, spironolactone 20 mg and valsartan 160mg. The initial dose of valsartan will be 80mg per day and will be doubled to 160mg per day 2 weeks later and then maintain until the end of the 8-week treatment period.
Study: NCT06447103
Drug: Zirconium Zr 89 Girentuximab
Normalized name: zirconium
DrugBank: Girentuximab (DB05304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05136560
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intervention drugs would be administered for 1 or 2 days.
Study: NCT04518228
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
Study: NCT04518228
Drug: Tenofovir alafenamide (TAF)
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants
Study: NCT04518228
Drug: Cabotegravir (CAB)
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered consistent with the package inserts and/or instructions provided by the non-study sources who prescribe or supply the drugs to participants